triiodothyronine and Nodular Goiter studies

Triiodothyronine: A T3 thyroid hormone normally synthesized and secreted by the thyroid gland in much smaller quantities than thyroxine (T4). Most T3 is derived from peripheral monodeiodination of T4 at the 5' position of the outer ring of the iodothyronine nucleus. The hormone finally delivered and used by the tissues is mainly T3.
3,3',5-triiodo-L-thyronine : An iodothyronine compound having iodo substituents at the 3-, 3'- and 5-positions. Although some is produced in the thyroid, most of the 3,3',5-triiodo-L-thyronine in the body is generated by mono-deiodination of L-thyroxine in the peripheral tissues. Its metabolic activity is about 3 to 5 times that of L-thyroxine. The sodium salt is used in the treatment of hypothyroidism.

Research Excerpts

Excerpt	Relevance	Reference
"Consecutive patients with hyperthyroidism caused by Graves' disease or by multinodular toxic goiter were randomized to be treated with high-dose propylthiouracil (PTU) to block D1, PTU plus KI, or PTU plus sodium ipodate to additionally block D2."	9.12	Sources of circulating 3,5,3'-triiodothyronine in hyperthyroidism estimated after blocking of type 1 and type 2 iodothyronine deiodinases. ( Christensen, SE; Helleberg, K; Laurberg, P; Nielsen, S; Pedersen, KM; Seefeldt, T; Vestergaard, H, 2007)
"In this study, 35 patients with euthyroid diffuse goiter and 35 patients with euthyroid nodular goiter were treated with Levothyroxine (L-T4) for six months."	9.09	Suppressive therapy with levothyroxine for euthyroid diffuse and nodular goiter. ( Başkal, N; Erdoğan, G; Güllü, S; Gürses, MA; Kamel, AN; Uysal, AR, 1999)
" To investigate this discrepancy we determined TNF-alpha and interleukin 6 (IL-6) levels in 25 hyperthyroid patients who responded to propylthiouracil treatment (16 with Graves' disease and nine with toxic multinodular goiter) and compared them with the levels found in euthyroid patients with simple diffuse goiter (n = 15) and normal healthy controls (n = 15)."	9.08	Serum levels of interleukin 6 and tumor necrosis factor-alpha in hyperthyroid patients before and after propylthiouracil treatment. ( Akalin, S; Celik, I; Erbaş, T, 1995)
" In a prospective, controlled trial, ninety-two adult volunteers with Graves' disease, toxic autonomous nodule or toxic multinodular goiter were randomly assigned into the following treatment protocols: Group 1, 30 mg of methimazole (MMI) and 20 g of colestipol-hydrochloride (COL) daily; Group 2, 30 mg of MMI daily; and Group 3, 15 mg of MMI 20 g of COL daily."	9.08	Role of colestipol in the treatment of hyperthyroidism. ( Hagag, P; Nissenbaum, H; Weiss, M, 1998)
"Amiodarone-induced thyrotoxicosis is a life-threatening condition."	7.74	Combination of minimally invasive thyroid surgery and local anesthesia associated to iopanoic acid for patients with amiodarone-induced thyrotoxicosis and severe cardiac disorders: a pilot study. ( Ambrosini, CE; Berti, P; Bogazzi, F; Martino, E; Materazzi, G; Miccoli, P, 2007)
"Amiodarone-induced thyrotoxicosis (AIT) may be caused by excessive thyroidal hormone synthesis and release (type 1) or by a destructive process (type 2)."	7.74	Color-flow Doppler sonography in the differential diagnosis and management of amiodarone-induced thyrotoxicosis. ( Cianchetti, ME; Loy, M; Mariotti, S; Melis, A; Perra, E; Piga, M; Pinna, G; Serra, A, 2007)
"In SWG, a recently iodine-sufficient region, the risk of developing hyperthyroidism in patients with NTNG after administration of 100-150 microg T4 is relatively high in those whose serum TSH before T4 treatment is in the lower normal range."	7.74	The odyssey of nontoxic nodular goiter (NTNG) in Greece under suppression therapy, and after improvement of iodine deficiency. ( Kyriazopoulou, V; Markou, KB; Michalaki, M; Paraskevopoulou, P; Vagenakis, AG, 2008)
"Amiodarone-induced thyrotoxicosis (AIT) is a challenging management problem, since patients treated with amiodarone invariably have underlying heart disease."	7.73	Amiodarone-induced thyrotoxicosis: left ventricular dysfunction is associated with increased mortality. ( Diamond, T; Lewis, M; O'Sullivan, AJ, 2006)
"A high incidence of toxic nodular goiter has recently been described in areas of relatively low iodine intake."	7.69	Development of hyperthyroidism in nodular goiter and thyroid malignancies in an area of relatively low iodine intake. ( Knudsen, N; Kristensen, HL; Siersbaek-Nielsen, K; Vadstrup, S, 1995)
"The aim of this investigation was to evaluate the efficacy of levothyroxine suppressive therapy in the medical management of nontoxic benign multinodular goiter."	7.68	Levothyroxine suppressive therapy in the medical management of nontoxic benign multinodular goiter. ( Celani, MF, 1993)
"Hypothyroxinemia and hypertriiodothyroninemia may occur in the course of antithyroid drug or 131I treatment for hyperthyroid Graves' disease and toxic multinodular goiter."	7.68	Discordant hypothyroxinemia and hypertriiodothyroninemia in treated patients with hyperthyroid Graves' disease and toxic multinodular goiter. ( Akalin, S; Gedik, O; Ozdemir, T, 1991)
"The sequential changes in serum thyroglobulin (Tg), thyroxine (T4), free thyroxine (FT4), triiodothyronine (T3) and thyrotropin (TSH) were evaluated in ten patients on whom partial thyroidectomy for nontoxic nodular goiter had been performed."	7.67	Sequential changes in serum thyroglobulin, triiodothyronine, and thyroxine following partial thyroidectomy for nontoxic nodular goiter. ( Adachi, T; Hori, S; Igawa, O; Mashiba, H; Mitani, Y; Shigemasa, C; Taniguchi, S; Ueta, Y; Yamauchi, N; Yoshida, A, 1988)
"Serum immunoreactive parathyroid hormone (S-iPTH) was measured together with serum and urinary calcium and phosphorus in 45 hyperthyroid patients in order to assess parathyroid fe of hyperthyroidism."	7.65	Decreased parathyroid function in hyperthyroidism: interrelationships between serum parathyroid hormone, calcium-phosphorus metabolism and thyroid function. ( Christensen, MS; Mosekilde, L, 1977)
"Twenty-one patients with goiters-four diffuse and 17 nodular-were treated with I-triiodothyronine and I-thyroxine in doses to tolerance."	7.64	Non-toxic goiter treatment with 1-triiodothyronine and 1-thyroxine. ( CATZ, B; FAWELL, WN, 1963)
"On follow-up 1 year after treatment for Graves' disease, we repeated the measurement of the levels of sHLA-1 in 21 patients."	5.31	Levels of soluble human leukocyte antigen class 1 are increased in Graves' disease and toxic multinodular goiter and correlate with the levels of triiodothyronine. ( McDonald, J; Yaturu, S, 2002)
" Criterion of adequate LT4 dosage was a negative TRH test after dose titration in increments of 25 micrograms/d."	5.27	[Optimization of levothyroxine treatment. Dosage dependence on the existing parenchymal mass, age, body weight and fasting intake]. ( Wenzel, KW, 1986)
"Consecutive patients with hyperthyroidism caused by Graves' disease or by multinodular toxic goiter were randomized to be treated with high-dose propylthiouracil (PTU) to block D1, PTU plus KI, or PTU plus sodium ipodate to additionally block D2."	5.12	Sources of circulating 3,5,3'-triiodothyronine in hyperthyroidism estimated after blocking of type 1 and type 2 iodothyronine deiodinases. ( Christensen, SE; Helleberg, K; Laurberg, P; Nielsen, S; Pedersen, KM; Seefeldt, T; Vestergaard, H, 2007)
"Radioiodine (131I) is increasingly used as treatment for volume reduction of nontoxic, nodular goiter."	5.09	Administration of a single low dose of recombinant human thyrotropin significantly enhances thyroid radioiodide uptake in nontoxic nodular goiter. ( Bravenboer, B; Bus, JW; Erdtsieck, RJ; Hermus, AR; Huysmans, DA; Nieuwlaat, WA; Schellekens, AP, 2000)
"In this study, 35 patients with euthyroid diffuse goiter and 35 patients with euthyroid nodular goiter were treated with Levothyroxine (L-T4) for six months."	5.09	Suppressive therapy with levothyroxine for euthyroid diffuse and nodular goiter. ( Başkal, N; Erdoğan, G; Güllü, S; Gürses, MA; Kamel, AN; Uysal, AR, 1999)
" In a prospective, controlled trial, ninety-two adult volunteers with Graves' disease, toxic autonomous nodule or toxic multinodular goiter were randomly assigned into the following treatment protocols: Group 1, 30 mg of methimazole (MMI) and 20 g of colestipol-hydrochloride (COL) daily; Group 2, 30 mg of MMI daily; and Group 3, 15 mg of MMI 20 g of COL daily."	5.08	Role of colestipol in the treatment of hyperthyroidism. ( Hagag, P; Nissenbaum, H; Weiss, M, 1998)
" To investigate this discrepancy we determined TNF-alpha and interleukin 6 (IL-6) levels in 25 hyperthyroid patients who responded to propylthiouracil treatment (16 with Graves' disease and nine with toxic multinodular goiter) and compared them with the levels found in euthyroid patients with simple diffuse goiter (n = 15) and normal healthy controls (n = 15)."	5.08	Serum levels of interleukin 6 and tumor necrosis factor-alpha in hyperthyroid patients before and after propylthiouracil treatment. ( Akalin, S; Celik, I; Erbaş, T, 1995)
"The standard treatment of hypothyroidism is levothyroxine (LT-4)."	4.02	Use of Thyroid Hormones in Hypothyroid and Euthyroid Patients: A 2020 THESIS Questionnaire Survey of Members of the Swedish Endocrine Society. ( Attanasio, R; Hegedüs, L; Lantz, M; Nagy, EV; Papini, E; Perros, P; Planck, T, 2021)
"To characterize thyroid hormone levels at the time of diagnosis in the nosological types of thyrotoxicosis diagnosed in the population and to analyze determinants for serum thyroxine (T4) and tri-iodothyronine (T3)."	3.79	Determinants of serum T4 and T3 at the time of diagnosis in nosological types of thyrotoxicosis: a population-based study. ( Carlé, A; Knudsen, N; Laurberg, P; Ovesen, L; Pedersen, IB; Perrild, H; Rasmussen, LB, 2013)
"In SWG, a recently iodine-sufficient region, the risk of developing hyperthyroidism in patients with NTNG after administration of 100-150 microg T4 is relatively high in those whose serum TSH before T4 treatment is in the lower normal range."	3.74	The odyssey of nontoxic nodular goiter (NTNG) in Greece under suppression therapy, and after improvement of iodine deficiency. ( Kyriazopoulou, V; Markou, KB; Michalaki, M; Paraskevopoulou, P; Vagenakis, AG, 2008)
"Amiodarone-induced thyrotoxicosis (AIT) may be caused by excessive thyroidal hormone synthesis and release (type 1) or by a destructive process (type 2)."	3.74	Color-flow Doppler sonography in the differential diagnosis and management of amiodarone-induced thyrotoxicosis. ( Cianchetti, ME; Loy, M; Mariotti, S; Melis, A; Perra, E; Piga, M; Pinna, G; Serra, A, 2007)
"Amiodarone-induced thyrotoxicosis is a life-threatening condition."	3.74	Combination of minimally invasive thyroid surgery and local anesthesia associated to iopanoic acid for patients with amiodarone-induced thyrotoxicosis and severe cardiac disorders: a pilot study. ( Ambrosini, CE; Berti, P; Bogazzi, F; Martino, E; Materazzi, G; Miccoli, P, 2007)
"To examine the natural history of a subnormal serum thyroid-stimulating hormone (TSH) concentration with normal concentrations of both serum free thyroxine (FT4) and free triiodothyronine (FT3) (subclinical hyperthyroidism)."	3.73	Observations concerning the natural history of subclinical hyperthyroidism. ( Woeber, KA, 2005)
"Chronic exposure to high doses of iodine induces thyroid dysfunction, but effects of chronic exposure to high amounts of iodine on pregnancy and fetal outcome are uncertain."	3.73	Developmental toxic effects of chronic exposure to high doses of iodine in the mouse. ( Guo, HL; Hao, LP; Hou, XH; Liu, LG; Sun, XF; Xu, J; Yang, XF; Yao, P, 2006)
"Amiodarone-induced thyrotoxicosis (AIT) is a challenging management problem, since patients treated with amiodarone invariably have underlying heart disease."	3.73	Amiodarone-induced thyrotoxicosis: left ventricular dysfunction is associated with increased mortality. ( Diamond, T; Lewis, M; O'Sullivan, AJ, 2006)
"A comparison of triiodothyronine and thyroxin binding to red blood cells sampled from children and adolescents with such thyroid pathologies as cancer, adenoma, nodular goiter and thyroiditis, on the one hand, and healthy children, on the other, has established significant changes in the hormone-binding activity of erythrocytes in thyroid cancer patients."	3.71	[Triiodothyronine and thyroxin binding to red blood cells in children and adolescents with thyroid cancer]. ( Demidchik, IuE; Fedorovich, EI, 2002)
" We described four patients treated for nodular goiter, where clinical and biochemical studies before and after triiodothyronine treatment (by increasing doses from 20 micrograms to 100 micrograms daily for 10 days) have made it possible to diagnose the Refetoff syndrome."	3.70	[Generalized resistance to thyroid hormones in four patients with nodular goiter]. ( Gradecka-Kubik, I; Lacka, K, 1998)
"A high incidence of toxic nodular goiter has recently been described in areas of relatively low iodine intake."	3.69	Development of hyperthyroidism in nodular goiter and thyroid malignancies in an area of relatively low iodine intake. ( Knudsen, N; Kristensen, HL; Siersbaek-Nielsen, K; Vadstrup, S, 1995)
"To investigate the pathogenesis of post-thyroidectomy hypocalcemia calcium, phosphate, calcitonin, parathormone, albumin, triiodothyronine and thyroxine levels were monitored during operation and postoperatively in 25 female patients undergoing bilateral subtotal thyroidectomy for non-toxic nodular goiter."	3.69	Post-thyroidectomy hypocalcemia: the role of calcitonin, parathormone and serum albumin. ( Bumin, C; Cakmakli, S; Cavusoglu, T; Torun, N, 1996)
" In this study, RBC CAI concentrations were measured in patients with thyroid nodules who were receiving suppressive doses of thyroxine (group I) and compared with those obtained in patients with primary hypothyroidism receiving replacement doses of thyroxine (group 2)."	3.68	Erythrocyte carbonic anhydrase I concentration in patients receiving thyroxine. ( Fukazawa, H; Kaise, K; Kaise, N; Kikuchi, K; Kiso, Y; Kurihara, H; Mori, K; Yoshida, K; Yoshinaga, K, 1991)
"Hypothyroxinemia and hypertriiodothyroninemia may occur in the course of antithyroid drug or 131I treatment for hyperthyroid Graves' disease and toxic multinodular goiter."	3.68	Discordant hypothyroxinemia and hypertriiodothyroninemia in treated patients with hyperthyroid Graves' disease and toxic multinodular goiter. ( Akalin, S; Gedik, O; Ozdemir, T, 1991)
"The aim of this investigation was to evaluate the efficacy of levothyroxine suppressive therapy in the medical management of nontoxic benign multinodular goiter."	3.68	Levothyroxine suppressive therapy in the medical management of nontoxic benign multinodular goiter. ( Celani, MF, 1993)
"The relationship between T4, T3 and T4/T3 ratio in thyroid nodules/paranodular tissues, thyroid and peripheral veins has been investigated in 26 patients with nontoxic nodular goiters; eleven of them were treated with l-thyroxine 150 micrograms daily."	3.67	Relationship between T4, T3 and T4/T3 ratio in thyroid tissue, thyroid and peripheral veins in patients with nontoxic nodular goiter. ( Pegan, B; Petric, V; Solter, M; Tislarić, D, 1989)
"The sequential changes in serum thyroglobulin (Tg), thyroxine (T4), free thyroxine (FT4), triiodothyronine (T3) and thyrotropin (TSH) were evaluated in ten patients on whom partial thyroidectomy for nontoxic nodular goiter had been performed."	3.67	Sequential changes in serum thyroglobulin, triiodothyronine, and thyroxine following partial thyroidectomy for nontoxic nodular goiter. ( Adachi, T; Hori, S; Igawa, O; Mashiba, H; Mitani, Y; Shigemasa, C; Taniguchi, S; Ueta, Y; Yamauchi, N; Yoshida, A, 1988)
" T4 and TSH concentrations in the following groups of patients: a) three patients submitted to surgical removal of a solitary, autonomous thyroid nodule which had completely inhibited the extranodular tissue; b) five subjects, with the same disease, in whom functional recovery of the extranodular tissue was induced by increased circulating TSH levels, produced by treatment with methimazole; c) one patient submitted to hemithyroidectomy for multinodular goitre; d) two hyperthyroid patients who had been treated with methimazole."	3.66	Effect of endogenous thyroid stimulating hormone levels on the secretion of thyroid hormones in man. ( Bianchi, R; Carpi, A; Cocci, LF; Del Corso, L; Giannessi, D; Levanti, C; Mariani, G; Zucchelli, GC, 1979)
"Radioimmunoassay of thyroxine and triiodothyronine in a 14-year-old girl with primary hypothyroidism and nodular goitre as a result of Hashimoto's thyroiditis gave falsely low values due to the presence of hormone-binding antibodies."	3.65	[False radioimmuno-assay of thyroxine and triiodothyronine in the presence of hormone-binding autoantibodies in serum (author's transl)]. ( Herrmann, J; Kley, HK; Kröll, HJ; Krüskemper, HL; Rudorff, KH, 1976)
"Serum immunoreactive parathyroid hormone (S-iPTH) was measured together with serum and urinary calcium and phosphorus in 45 hyperthyroid patients in order to assess parathyroid fe of hyperthyroidism."	3.65	Decreased parathyroid function in hyperthyroidism: interrelationships between serum parathyroid hormone, calcium-phosphorus metabolism and thyroid function. ( Christensen, MS; Mosekilde, L, 1977)
"Twenty-one patients with goiters-four diffuse and 17 nodular-were treated with I-triiodothyronine and I-thyroxine in doses to tolerance."	3.64	Non-toxic goiter treatment with 1-triiodothyronine and 1-thyroxine. ( CATZ, B; FAWELL, WN, 1963)
"Radioiodine (RAI) treatment for hyperthyroidism is a very common modality, chosen by physicians worldwide."	1.56	Predictors of euthyreosis in hyperthyroid patients treated with radioiodine ( Budlewski, T; Franek, E; Gryn, T; Kałuża, B; Stachura, A, 2020)
"Obesity is closely related to thyroid hormones; however, the relationship between abdominal fat distribution and thyroid hormones has rarely been explored."	1.56	Association between Abdominal Fat Distribution and Free Triiodothyronine in a Euthyroid Population. ( Bao, Y; Ma, X; Nie, X; Wang, Y; Xiao, Y; Xu, Y, 2020)
"Benign breast diseases were detected in 54."	1.42	The prevalence of benign breast diseases in patients with nodular goiter and Hashimoto's thyroiditis. ( Anil, C; Guney, T; Gursoy, A, 2015)
"Huge follicles corresponded to the cysts that were detected by ultrasonography."	1.37	Pathologic features of polycystic thyroid disease: comparison with benign nodular goiter. ( Amino, N; Hirokawa, M; Ito, M; Ito, Y; Kubota, S; Kudo, T; Miyauchi, A; Nishihara, E; Takamura, Y; Tamai, H, 2011)
"The odds ratio (ORs) for the risk of thyroid cancer with a serum TSH between 0."	1.36	Are endogenously lower serum thyroid hormones new predictors for thyroid malignancy in addition to higher serum thyrotropin? ( Baser, H; Cakir, B; Dirikoc, A; Ersoy, R; Gul, K; Oguz, A; Ozdemir, D; Tuzun, D, 2010)
"In patients with Graves' disease, serum-free T₃ levels were inversely correlated with TFPI Ag levels (r: -0."	1.35	Increased thrombin-activatable fibrinolysis inhibitor and decreased tissue factor pathway inhibitor in patients with hyperthyroidism. ( Erem, C; Ersoz, HO; Kocak, M; Nuhoglu, İ; Ucuncu, O; Yilmaz, M, 2009)
"In subjects with Graves' disease, we propose using a pre-determined 131I activity, which is higher than that derived from the guidelines."	1.35	Radiometabolic treatment of hyperthyroidism with a calculated dose of 131-iodine: results of one-year follow-up. ( Condorelli, A; Latina, A; Marturano, I; Pezzino, V; Regalbuto, C, 2009)
"In hyperthyroid Graves' disease, short-term methimazole is sufficient to induce lasting remission in some patients, but even long-term treatment fails to do so in others."	1.31	An elevation of serum immunoglobulin E provides a new aspect of hyperthyroid Graves' disease. ( Eto, S; Ito, Y; Komiya, I; Nishimori, T; Sato, A; Tanaka, Y; Terao, A; Yamada, T, 2000)
"The findings show that untreated toxic multinodular goiter causes profound alterations in components of the antioxidant system in erythrocytes indicative of increased oxidative stress."	1.31	Erythrocyte, plasma, and serum antioxidant activities in untreated toxic multinodular goiter patients. ( Alicigüzel, Y; Karayalçin, U; Ozdem, SN; Ozdem, SS; Perry, G; Siedlak, SL; Smith, MA, 2001)
"We report a case of follicular thyroid carcinoma discovered after surgical treatment of a toxic multinodular goiter, in which solitary adrenal gland metastasis was detected five years later."	1.31	Solitary adrenal gland metastasis of a follicular thyroid carcinoma presenting with hyperthyroidism. ( López-Aznar, D; Ponce, JL; Prieto, M; Sancho-Fornos, S; Yunta, PJ, 2001)
"Seven patients with Graves' disease, eight with toxic nodular goiter and seven with non-toxic nodular goiter, were followed after 131I-treatment."	1.31	Serum levels of the cytokines IL-1beta, IL-6 and ICAM-1 after 131I-treatment of Graves' disease and nodular goiter. ( Faber, J; Jarløv, AE; Kristensen, LO; Nygaard, B, 2000)
"On follow-up 1 year after treatment for Graves' disease, we repeated the measurement of the levels of sHLA-1 in 21 patients."	1.31	Levels of soluble human leukocyte antigen class 1 are increased in Graves' disease and toxic multinodular goiter and correlate with the levels of triiodothyronine. ( McDonald, J; Yaturu, S, 2002)
"In 26 patients with untreated Graves' disease and 7 hyperthyroid patients with Hashimoto's thyroiditis, the mean levels of soluble IL-2 receptor were both significantly higher than in normal controls (1497 +/- 649 (mean +/- SD), 641 +/- 137 vs 221 +/- 63 10(3) U/l, p less than 0."	1.28	Increased soluble interleukin 2 receptor levels in autoimmune thyroid disease. ( Nakanishi, K; Ohta, Y; Taniguchi, Y, 1991)
"In case of a functioning thyroid adenoma detected by scintigraphy, the basal TSH concentration of the serum over 0."	1.27	Examination of serum thyrotropic hormone level by 'supersensitive' immunoradiometric assay in functioning thyroid adenoma. ( Bános, C; Csillag, J; Földes, J; Lakatos, P; Tarján, G, 1987)
" Criterion of adequate LT4 dosage was a negative TRH test after dose titration in increments of 25 micrograms/d."	1.27	[Optimization of levothyroxine treatment. Dosage dependence on the existing parenchymal mass, age, body weight and fasting intake]. ( Wenzel, KW, 1986)
"Hence patients with Graves' disease having a small thyroid gland should be treated medically while surgery or radioiodine may be a more reasonable choice in Graves' patients with medium size or large goitres."	1.27	Goitre size and outcome of medical treatment of Graves' disease. ( Buchholtz Hansen, PE; Eskjaer Jensen, S; Iversen, E; Laurberg, P; Weeke, J, 1986)

Timeframe	Studies, this research(%)	All Research%
pre-1990	126 (55.51)	18.7374
1990's	38 (16.74)	18.2507
2000's	38 (16.74)	29.6817
2010's	19 (8.37)	24.3611
2020's	6 (2.64)	2.80

Trial			Phase	Enrollment	Study Type	Start Date	Status
Pretreatment With Recombinant Human Thyrotropin (rhTSH) for the Effect on Thyroid Size and Function, and for the Effect of Radioiodine Treatment in Patients With Nodular Goiter. Prospective, Randomized Double-blinded Trials.[NCT00145366]			Phase 2	110 participants	Interventional	2002-04-30	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Article	Year
[T3 toxicosis]. Nihon rinsho. Japanese journal of clinical medicine, 2006, May-28, Volume: Suppl 1 Topics: Adrenergic beta-Antagonists; Antithyroid Agents; Diagnosis, Differential; Goiter, Nodular; Graves Di	2006
[Role of disorders of the hypothalamo-hypophyseo-thyroid system in the development of postoperative hypothyroidism]. Terapevticheskii arkhiv, 1983, Volume: 55, Issue:10 Topics: Adolescent; Adult; Autoimmune Diseases; Feedback; Female; Goiter; Goiter, Nodular; Humans; Hyperthyr	1983
The medical treatment of non-toxic goiter: several questions remain. Thyroidology, 1993, Volume: 5, Issue:2 Topics: Drug Therapy, Combination; Goiter, Nodular; Humans; Iodine; Thyroxine; Triiodothyronine	1993
Anaplastic thyroid cancer with transient thyrotoxicosis: case report and literature review. Thyroid : official journal of the American Thyroid Association, 1999, Volume: 9, Issue:10 Topics: Biopsy; Carcinoma; Fatal Outcome; Female; Goiter, Nodular; Humans; Middle Aged; Propranolol; Thyroid	1999
Localized non-Hodgkin's lymphoma of the adrenal and thyroid glands. Endocrinologia japonica, 1992, Volume: 39, Issue:3 Topics: Addison Disease; Adrenal Gland Neoplasms; Adrenal Glands; Adrenocorticotropic Hormone; Antineoplasti	1992
Aetiology of hyperthyroidism. I. British medical journal, 1974, Aug-17, Volume: 3, Issue:5928 Topics: Africa; Age Factors; Chromatography, Paper; Europe; Female; Goiter, Nodular; Graves Disease; Humans;	1974
An approach to diagnosis and therapy of thyroid tumors. Seminars in nuclear medicine, 1971, Volume: 1, Issue:4 Topics: Adult; Age Factors; Biopsy; Diagnosis, Differential; Female; Goiter; Goiter, Nodular; Humans; Male;	1971

Article	Year
Short term effects of levothyroxine treatment in thyroid multinodular disease. Endocrine journal, 2010, Volume: 57, Issue:9 Topics: Adult; Female; Goiter, Nodular; Humans; Middle Aged; Premenopause; Thyroid Gland; Thyrotropin; Thyro	2010
The influence of non-radioactive iodine (127I) on the outcome of radioiodine (131I) therapy in patients with Graves' disease and toxic nodular goitre. Nuclear medicine review. Central & Eastern Europe, 2011, Volume: 14, Issue:1 Topics: Female; Goiter, Nodular; Graves Disease; Half-Life; Humans; Iodine; Iodine Radioisotopes; Male; Midd	2011
Administration of a single dose of recombinant human thyrotrophin enhances the efficacy of radioiodine treatment of large compressive multinodular goitres. Clinical endocrinology, 2004, Volume: 60, Issue:3 Topics: Aged; Analysis of Variance; Combined Modality Therapy; Female; Goiter, Nodular; Humans; Iodine; Iodi	2004
Low-dose recombinant human thyrotropin-aided radioiodine treatment of large, multinodular goiters in elderly patients. European journal of endocrinology, 2006, Volume: 154, Issue:2 Topics: Aged; Aged, 80 and over; Dose-Response Relationship, Radiation; Female; Goiter, Nodular; Humans; Iod	2006
Stimulation with 0.3-mg recombinant human thyrotropin prior to iodine 131 therapy to improve the size reduction of benign nontoxic nodular goiter: a prospective randomized double-blind trial. Archives of internal medicine, 2006, Jul-24, Volume: 166, Issue:14 Topics: Adult; Aged; Antithyroid Agents; Disease Progression; Dose-Response Relationship, Drug; Double-Blind	2006
Sources of circulating 3,5,3'-triiodothyronine in hyperthyroidism estimated after blocking of type 1 and type 2 iodothyronine deiodinases. The Journal of clinical endocrinology and metabolism, 2007, Volume: 92, Issue:6 Topics: Adolescent; Adult; Antithyroid Agents; Child; Drug Therapy, Combination; Female; Goiter, Nodular; Gr	2007
Serum levels of interleukin 6 and tumor necrosis factor-alpha in hyperthyroid patients before and after propylthiouracil treatment. European journal of endocrinology, 1995, Volume: 132, Issue:6 Topics: Adult; Female; Goiter, Nodular; Graves Disease; Humans; Hyperthyroidism; Interleukin-6; Male; Middle	1995
Separation of autonomous function from cell density in non-immunogenic hyperthyroidism--II. quantified comparison before and after radioiodine therapy. Nuklearmedizin. Nuclear medicine, 1996, Volume: 35, Issue:1 Topics: Follow-Up Studies; Goiter, Nodular; Humans; Hyperthyroidism; Iodine Radioisotopes; Radionuclide Imag	1996
Increased urinary thyroxine sulfate excretion in thyroxine therapy. Endocrine journal, 1997, Volume: 44, Issue:4 Topics: Adult; Female; Goiter, Nodular; Humans; Linear Models; Premenopause; Radioimmunoassay; Thyroxine; Tr	1997
Role of colestipol in the treatment of hyperthyroidism. Journal of endocrinological investigation, 1998, Volume: 21, Issue:11 Topics: Adult; Antithyroid Agents; Colestipol; Female; Goiter, Nodular; Graves Disease; Humans; Hyperthyroid	1998
Suppressive therapy with levothyroxine for euthyroid diffuse and nodular goiter. Endocrine journal, 1999, Volume: 46, Issue:1 Topics: Female; Goiter; Goiter, Nodular; Humans; Iodine Radioisotopes; Male; Thyroglobulin; Thyroid Gland; T	1999
Administration of a single low dose of recombinant human thyrotropin significantly enhances thyroid radioiodide uptake in nontoxic nodular goiter. The Journal of clinical endocrinology and metabolism, 2000, Volume: 85, Issue:10 Topics: Adult; Aged; Female; Goiter, Nodular; Humans; Iodine; Iodine Radioisotopes; Male; Middle Aged; Recom	2000

triiodothyronine and Nodular Goiter

Research Excerpts

Research

Studies (227)

Authors

Clinical Trials (1)

Trial Overview

Reviews

Trials

Other Studies

Authors	Studies
Planck, T	1
Lantz, M	1
Perros, P	1
Papini, E	1
Attanasio, R	1
Nagy, EV	1
Hegedüs, L	2
Lee, MY	1
Maahs, DM	1
Li, Q	2
Lu, M	1
Wang, NJ	1
Chen, Y	1
Chen, YC	1
Han, B	1
Xia, FZ	1
Jiang, BR	1
Zhai, HL	1
Lin, DP	1
Lu, YL	1
Stachura, A	1
Gryn, T	1
Kałuża, B	1
Budlewski, T	1
Franek, E	1
Nie, X	1
Xu, Y	1
Ma, X	1
Xiao, Y	1
Wang, Y	1
Bao, Y	1
Okazaki-Hada, M	1
Maruoka, A	1
Yamamoto, M	1
Ito, M	2
Hirokawa, M	2
Nishikawa, M	1
Akamizu, T	2
Miyauchi, A	2
Toyoda, N	1
Khan, SH	1
Fazal, N	1
Ijaz, A	1
Manzoor, SM	1
Asif, N	1
Rafi, T	1
Yasir, M	1
Niazi, NK	1
Kuznik, BI	1
Vitkovsky, YA	1
Gvozdeva, OV	1
Solpov, AV	1
Magen, E	1
Carlé, A	1
Knudsen, N	2
Pedersen, IB	1
Perrild, H	1
Ovesen, L	1
Rasmussen, LB	1
Laurberg, P	5
Abbas, R	1
Abbas, HG	1
Shahid, A	1
Chand, S	1
Nawaz, S	1
Anil, C	1
Guney, T	1
Gursoy, A	1
Goichot, B	1
Caron, P	1
Landron, F	1
Bouée, S	1
Michalaki, M	1
Kyriazopoulou, V	1
Paraskevopoulou, P	1
Vagenakis, AG	1
Markou, KB	1
Bossowski, A	2
Czarnocka, B	1
Bardadin, K	1
Urban, M	2
Niedziela, M	1
Dadan, J	1
Regalbuto, C	1
Marturano, I	1
Condorelli, A	1
Latina, A	1
Pezzino, V	1
Di Luigi, L	1
Parisi, A	1
Quaranta, F	1
Romanelli, F	1
Tranchita, E	1
Sgrò, P	1
Nardi, P	1
Fattorini, G	1
Cavaliere, R	2
Pigozzi, F	1
D'Armiento, M	1
Lenzi, A	1
Gen, R	1
Akbay, E	1
Camsari, A	1
Ozcan, T	1
Andrikoula, M	1
Kolaitis, N	1
Vartholomatos, G	1
Tsatsoulis, A	1
Erem, C	2
Ucuncu, O	1
Yilmaz, M	1
Kocak, M	2
Nuhoglu, İ	1
Ersoz, HO	2
Boelaert, K	1
Torlinska, B	1
Holder, RL	1
Franklyn, JA	1
Paghera, B	1
Panarotto, MB	1
Maira, G	1
Magri, GC	1
Bertagna, F	1
Bosio, G	1
Rossini, P	1
De Agostini, A	1
Savelli, G	1
Lucchini, S	1
Giubbini, R	1
Cesareo, R	1
Iozzino, M	1
Isgrò, MA	1
Annunziata, F	1
Di Stasio, E	1
Gul, K	1
Ozdemir, D	1
Dirikoc, A	1
Oguz, A	1
Tuzun, D	1
Baser, H	1
Ersoy, R	1
Cakir, B	1
Akinci, B	1
Demir, T	1
Comlekci, A	1
Yener, S	1
Ozcan, MA	1
Karaoglu, O	1
Yuksel, F	1
Secil, M	1
Yesil, S	1
Aslan, M	1
Cosar, N	1
Celik, H	1
Aksoy, N	1
Dulger, AC	1
Begenik, H	1
Soyoral, YU	1
Kucukoglu, ME	1
Selek, S	1
Kubota, S	1
Takamura, Y	1
Ito, Y	2
Tamai, H	2
Kudo, T	1
Nishihara, E	1
Amino, N	1
Rogowski, F	1
Abdelrazek, S	1
Szumowski, P	1
Zonenberg, A	1
Parfienczyk, A	1
Sawicka, A	1
Masannat, Y	1
Gandhy, R	1
Olajide, O	1
Kheetan, R	1
Yaqub, A	1
Ruggeri, RM	1
Campennì, A	1
Sindoni, A	1
Baldari, S	1
Trimarchi, F	2
Benvenga, S	2
González Cabrera, N	1
Kalic, AK	1
Antón Miguel, MÁ	1
Sierra Polo, P	1
Vicente Vicente, MÁ	1
Mamchych, VI	1
Pogorielov, OV	1
Voskoboĭnik, OIu	1
Yaturu, S	1
McDonald, J	1
Patel, VA	1
Logan, A	1
Watkinson, JC	1
Uz-Zaman, S	1
Sheppard, MC	1
Ramsden, JD	1
Eggo, MC	1
Fedorovich, EI	1
Demidchik, IuE	1
Stasiak-Barmuta, A	1
Custro, N	1
Ganci, A	1
Scafidi, V	1
Loviselli, A	1
Rizzolo, E	1
Mastinu, R	1
Velluzzi, F	1
Secci, G	1
Taberlet, A	1
Mariotti, S	2
FREEDBERG, AS	2
HAMOLSKY, MW	2
HINES, CR	1
WERNER, SC	1
ROW, VV	2
RADICHEVICH, I	1
FAWELL, WN	1
CATZ, B	1
JOHNSTON, MW	1
EZRIN, C	1
VOLPE, R	1
EBER, O	2
Silva, MN	1
Rubió, IG	1
Romão, R	1
Gebrin, EM	1
Buchpiguel, C	1
Tomimori, E	1
Camargo, R	1
Cardia, MS	1
Medeiros-Neto, G	1
Bayer, Y	1
Fasshauer, M	1
Paschke, R	1
Kandemir, N	1
Hacihasanoglu, A	1
Ukinc, K	1
Gasińska, T	2
Dec, R	1
Słomian, U	1
Starzewski, J	1
Woeber, KA	1
Appetecchia, M	1
Antonelli, A	2
Rotondi, M	2
Fallahi, P	2
Romagnani, P	2
Ferrari, SM	2
Barani, L	1
Ferrannini, E	2
Serio, M	2
Cohen, O	1
Ilany, J	1
Hoffman, C	1
Olchovsky, D	1
Dabhi, S	1
Karasik, A	1
Goshen, E	1
Rotenberg, G	1
Zwas, ST	1
O'Sullivan, AJ	1
Lewis, M	1
Diamond, T	1
Iwatani, Y	1
Nielsen, VE	1
Bonnema, SJ	1
Boel-Jørgensen, H	1
Grupe, P	1
Yang, XF	1
Xu, J	1
Hou, XH	1
Guo, HL	1
Hao, LP	1
Yao, P	1
Liu, LG	1
Sun, XF	1
Berti, P	1
Materazzi, G	1
Bogazzi, F	1
Ambrosini, CE	1
Martino, E	1
Miccoli, P	1
Grosso, M	1
Boni, G	1
Mariani, G	2
Vestergaard, H	2
Nielsen, S	1
Christensen, SE	1
Seefeldt, T	1
Helleberg, K	1
Pedersen, KM	2
Cavusoglu, T	2
Nurozler, AB	1
Titiz, C	1
Ustun, H	1
Aral, Y	1
Ozer, E	1
Kasim, R	1
Tezel, S	1
Loy, M	1
Perra, E	1
Melis, A	1
Cianchetti, ME	1
Piga, M	1
Serra, A	1
Pinna, G	1
Romanchishen, AF	1
Gostimskiĭ, AV	1
Skorodok, IuL	1
Ditkovskaia, LV	1
Smyth, PP	1
Neylan, D	1
O'Donovan, DK	1
Smeulers, J	3
Docter, R	3
Visser, TJ	3
Hennemann, G	3
Kuznetsov, AA	3
Shliakhta, AI	3
Tegler, L	1
Gillquist, J	1
Lindvall, R	1
Almqvist, S	1
Gemsenjäger, E	3
Girard, J	3
Kalinin, AP	1
Izmaĭlov, GI	1
Corrales Hernández, JJ	1
Martín, T	1
García Díez, LC	1
Miralles García, JM	1
Heberling, HJ	1
Heintze, M	1
Kuhlmann, E	1
Lohmann, D	1
Hartig, W	1
Mättig, H	1
Rybiński, K	2
Kuzdak, K	2
Semenov, VD	2
Mal'ginova, OV	1
Erezeeva, LA	1
Elte, JW	3
Bussemaker, JK	2
Termorshuizen, W	1
Goslings, BM	1
Roelfsema, F	1
Górowski, T	1
Czech, W	1
Kaniewski, M	1
Grinblat, J	1
Klein, A	1
Kipnowski, J	1
Meessen, H	1
Mori, H	1
Hamada, N	1
Mimura, T	1
Ito, K	3
Momotani, N	2
Nishikawa, Y	1
Abe, K	1
Konno, M	1
Sato, T	1
Matsuura, N	1
Baldet, L	2
Jaffiol, C	2
Földes, J	5
Bános, C	3
Krasznai, I	2
Haak, A	2
Wiarda, KS	1
Frölich, M	1
van der Velde, EA	1
van der Heide, D	1
Querido, A	1
Kirkegaard, C	4
Holme Jørgensen, P	1
Friis, T	3
Siersbaek-Nielsen, K	4
Meng, W	1
Meng, S	1
Hampel, R	1
Ventz, M	1
Zeisler, A	1
Sidora, VD	2
Puchalski, Z	1
Piotrowski, Z	1
Chyczewski, L	1
Orłowski, K	1
Jakubowska-Pakułowa, D	1
Zellmann, HE	3
Hurley, JR	1
Becker, DV	1
Dahlberg, PA	1
Karlsson, FA	1
Lundqvist, G	1
Mazurik, MF	1
Ponomarenko, AI	1
Ericsson, UB	1
Erfurth, EM	1
Schütz, A	1
Koutras, DA	2
Wenisch, C	1
Myskiw, D	1
Gessl, A	1
Graninger, W	1
Letizia, C	1
Minisola, S	1
Cerci, S	1
De Ciocchis, A	1
Coassin, S	1
D'Ambrosio, C	1
Scuro, L	1
Di Iorio, R	1
Gharib, H	2
Kristensen, HL	1
Vadstrup, S	1
Celik, I	1
Akalin, S	2
Erbaş, T	1
Tarján, G	4
Szathmari, M	1
Varga, F	1
Horvath, C	1
Celani, MF	1
Rieu, M	1
Bekka, S	1
Sambor, B	1
Berrod, JL	1
Fombeur, JP	1
Todorov, G	1
Petkov, R	1
Zakharieva, B	1
Kŭtev, N	1
Gavrailov, M	1
Evers, J	1
Scheid, H	1
Als, C	1
Rösler, H	1
Listewnik, M	1
Mori, T	2
Sugawa, H	1
Kosugi, S	1
Okuda, J	1
Cakmakli, S	1
Bumin, C	1
Torun, N	1
Huang, WS	1
Cherng, SC	1
Wang, CH	1
Shih, BF	1
Kuo, SW	1
Wu, SY	2
Wollmann, B	1
Meller, J	1
Hüfner, M	2
Becker, W	1
Sumino, H	1
Kanda, T	1
Kobayashi, I	1
Sakamoto, H	1
Sato, K	1
Sakamaki, T	1
Fukuda, T	1
Ichikawa, S	1
Nagai, R	1
Lacka, K	1
Gradecka-Kubik, I	1
Tonacchera, M	1
Vitti, P	1
Agretti, P	1
Giulianetti, B	1
Mazzi, B	1
Ceccarini, G	1
Fiore, E	1
Viacava, P	1
Naccarato, A	1
Pinchera, A	1
Chiovato, L	1
Hagag, P	1
Nissenbaum, H	1
Weiss, M	1
Siddiqi, A	1
Monson, JP	1
Wood, DF	1
Besser, GM	1
Burrin, JM	1
Güllü, S	1
Gürses, MA	1
Başkal, N	2
Uysal, AR	1
Kamel, AN	2
Erdoğan, G	2
Alagöl, F	1
Tanakol, R	1
Boztepe, H	1
Kapran, Y	1
Terzioglu, T	1
Dizdaroglu, F	1
Nakae, T	1
Kawanaka, M	1
Suehiro, M	1
Sugita, M	1
Fukuchi, M	1
Yamada, T	1
Sato, A	1
Komiya, I	1
Nishimori, T	1
Terao, A	1
Eto, S	1
Tanaka, Y	1
Nygaard, B	1
Jarløv, AE	1
Kristensen, LO	1
Faber, J	2
Huysmans, DA	1
Nieuwlaat, WA	1
Erdtsieck, RJ	1
Schellekens, AP	2
Bus, JW	1
Bravenboer, B	1
Hermus, AR	1
Taniyama, M	1
Ishikawa, N	1
Ban, Y	1
Alicigüzel, Y	1
Ozdem, SN	1
Ozdem, SS	1
Karayalçin, U	1
Siedlak, SL	1
Perry, G	1
Smith, MA	1
Luft, FC	1
Yunta, PJ	1
Ponce, JL	1
Prieto, M	1
López-Aznar, D	1
Sancho-Fornos, S	1
Körber, C	1
Schneider, P	1
Körber-Hafner, N	1
Hänscheid, H	1
Reiners, C	1
Lauridsen, UB	1
Staub, JJ	2
Heitz, P	1
Ishida, T	1
Sato, H	1
Hosono, O	1
Nakajima, H	1
Kawai, T	1
Horster, FA	2
Blichert-Toft, M	3
Egedorf, J	2
Christiansen, C	3
Axelsson, CK	2
Shiroozu, A	1
Volpert, EM	1
Shimaoka, K	1
Dige-Petersen, H	2
Hummer, L	2
Ibsen, H	1
Ibsen, J	2
Guilhaume, B	1
Meignan, M	1
Hazard, J	1
Bernheim, R	1
Perlemuter, L	1
Carpi, A	1
Bianchi, R	1
Zucchelli, GC	1
Del Corso, L	1
Levanti, C	1
Cocci, LF	1
Giannessi, D	1
Mosekilde, L	1
Christensen, MS	1
Wiersinga, WM	2
Touber, JL	2
Brun, R	1
Jenny, M	1
Junod, JP	1
Ishii, H	1
Takayama, H	1
Konishi, J	1
Kasagi, K	1
Endo, K	1
Torizuka, K	1
Feldt-Rasmussen, U	1
Bech, K	1
Date, J	1
Schultz, AL	1
Takeda, Y	1
Clemmensen, OJ	1
Vallee, G	1
Wahl, R	1
Grussendorf, M	1
Röher, HD	1
Livadas, DP	1
Souvatzoglou, A	1
Beckers, C	1
Jorgensen, SJ	1
Hansen, JB	1
Watt-Boolsen, S	1
Schwarz, F	1
Herrmann, J	1
Kley, HK	1
Rudorff, KH	1
Kröll, HJ	1
Krüskemper, HL	1
Hunter, R	1
Oakley, JR	1
Hamburger, JI	1
Marsden, P	1
Facer, P	1
Acosta, M	1
McKerron, CG	1
Hartwig, W	1
Green, WL	1
Dagci, SS	1
Akyar, S	1
Ekinci, C	1
Nakanishi, K	1
Taniguchi, Y	1
Ohta, Y	1
Gedik, O	1
Ozdemir, T	1
Vestergaard, P	1
Yoshida, K	1
Kiso, Y	1
Kurihara, H	1
Kaise, K	1
Kaise, N	1
Fukazawa, H	1
Mori, K	1
Kikuchi, K	1
Yoshinaga, K	1
Solter, M	4
Tislarić, D	4
Posavec, L	1
Pegan, B	3
Petric, V	3
Gabuniia, RI	1
Romanova, LF	1
Pinkera, A	1
Matiakin, EG	1
Duditskaia, TK	1
Federman, DD	1
Koukkou, E	1
Panayiotidis, P	1
Alevizou-Terzaki, V	1
Thalassinos, N	1
Berghout, A	1
Smits, NJ	1
Vana, S	1
Lakatos, P	3
Simons, RJ	1
Manni, A	1
Fang, SL	1
Braverman, L	1
Cooper, DS	1
Ridgway, EC	2
Yoshimura, H	1
Ozaki, O	1
Hosoya, T	1
Mérei, J	1
Holló, I	1
Morita, T	1
Ohshima, A	1
Komaki, G	1
Matsubayashi, S	1
Kuma, K	1
Nakagawa, T	1
Friis, J	1
Czernobilsky, H	1
Fiehn, W	1
Ziegler, R	1
Francomano, F	1
De Remigis, PL	1
Rossi, M	1
Cotellese, R	1
Capone, F	1
Ucchino, S	1
Mazzoni, L	1
Puglielli, L	1
Napolitano, AM	1
Sensi, S	1
Vermiglio, F	1
Melluso, R	1
Catalfamo, S	1
Princi, P	1
Battiato, S	1
Consolo, F	1
Csillag, J	1
Bregengård, C	2
Nowak, S	1
Prochaczek, F	1
Izbicka, M	1
Szydło, E	1
Nawrat, T	1
Becker, A	1
Shigemasa, C	1
Adachi, T	1
Igawa, O	1
Taniguchi, S	1
Mitani, Y	1
Ueta, Y	1
Hori, S	1
Yoshida, A	1
Yamauchi, N	1
Mashiba, H	1
Vesely, DL	1
Carvalho, DP	1
Rosenthal, D	1
Breitenbach, MM	1
Sekso, M	2
Poulsen, S	1
Hasselstrøm, K	1
Sørensen, BH	1
Wenzel, KW	1
Buchholtz Hansen, PE	1
Iversen, E	1
Eskjaer Jensen, S	1
Weeke, J	1
Lind, P	1
Thomas, CG	1
Tawil, M	1
Berman, MI	1
Nayfeh, SN	1
Dominis, M	1
Dralle, H	1
Lang, W	1
Pretschner, DP	1
Pichlmayr, R	1
Hesch, RD	1
Hollander, CS	1
Mitsuma, T	1
Nihei, N	1
Shenkman, L	1
Burday, SZ	1
Blum, M	1
Reinwein, D	1
Hackenberg, K	1
Pickardt, CR	1
Horn, K	1
Scriba, PC	1
Guinet, P	1
Monnier, L	1
Robin, M	1
Mirouze, J	1
Wilson, WW	1
Hör, G	1
Frey, KW	1
Gordin, A	1
Wägar, G	1
Hernberg, A	1
Liewendahl, K	1
Ruutu, R	1
Lamberg, BA	1
Zurcher, H	1
Sakoloff, C	1
Burger, A	1
Vallotton, MB	1
Nilsson, G	2
Mills, LC	1
Ríos, EP	1
Dutrem, MT	1
Ruíz, E	1
González, P	1
Valverde, C	1
Maisterrena, JA	1
Möller, T	1
Patel, YC	1
Burger, HG	1
Sanchez-Franco, F	1
García, MD	1
Cacicedo, L	1
Martin-Zurro, A	1
Escobar del Ray, F	1
Morreale de Escobar, G	1
Zoppetti, G	1
Cottino, F	1
Costa, A	1
Mertz, DP	1
Koch, B	1
Stelzer, M	1
Burman, KD	1
Earll, JM	1
Johnson, MC	1
Wartofsky, L	1
Taylor, S	1
Wildmeister, W	1
Hoffenberg, R	1
Popma, BH	1
Cloutier, MD	1
Hayles, AB	1
Nouel, JP	1
Brunelle, P	1
Segond, G	1
Ikkos, DG	1
Singelakis, P	1
Gonticas, SC	1
Weintraub, BD	1
Maloof, F	1
Stevenson, C	1
Silva, E	1
Pineda, G	1
Selenkow, HA	1
Karp, PJ	1
Wahner, HW	1
Wiggers, S	2
Nielsen, ES	2
Paaby, P	2